NASDAQ:XOMA - XOMA Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $24.10 +0.97 (+4.19 %) (As of 07/18/2018 04:00 PM ET)Previous Close$23.13Today's Range$22.76 - $24.3452-Week Range$6.86 - $37.25Volume82,906 shsAverage Volume131,521 shsMarket Capitalization$192.89 millionP/E Ratio24.59Dividend YieldN/ABeta2.91 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California. Receive XOMA News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:XOMA CUSIP98419J10 Webwww.xoma.com Phone510-204-7239 Debt Debt-to-Equity Ratio2.59 Current Ratio7.26 Quick Ratio7.26 Price-To-Earnings Trailing P/E Ratio24.59 Forward P/E Ratio-30.51 P/E GrowthN/A Sales & Book Value Annual Sales$52.69 million Price / Sales3.83 Cash Flow$2.2253 per share Price / Cash10.83 Book Value$0.71 per share Price / Book33.94 Profitability EPS (Most Recent Fiscal Year)$0.98 Net Income$14.59 million Net Margins40.44% Return on Equity-670.15% Return on Assets56.39% Miscellaneous Employees12 Outstanding Shares8,380,000Market Cap$192.89 XOMA (NASDAQ:XOMA) Frequently Asked Questions What is XOMA's stock symbol? XOMA trades on the NASDAQ under the ticker symbol "XOMA." How were XOMA's earnings last quarter? XOMA Corp (NASDAQ:XOMA) posted its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.07. The biotechnology company had revenue of $0.46 million for the quarter, compared to analyst estimates of $3.69 million. XOMA had a negative return on equity of 670.15% and a net margin of 40.44%. View XOMA's Earnings History. When is XOMA's next earnings date? XOMA is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for XOMA. What price target have analysts set for XOMA? 3 Wall Street analysts have issued 1-year target prices for XOMA's shares. Their predictions range from $33.00 to $49.00. On average, they expect XOMA's share price to reach $41.00 in the next year. This suggests a possible upside of 70.1% from the stock's current price. View Analyst Ratings for XOMA. What is the consensus analysts' recommendation for XOMA? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting XOMA? XOMA saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 905,211 shares, an increase of 73.6% from the June 15th total of 521,409 shares. Based on an average daily volume of 214,835 shares, the days-to-cover ratio is currently 4.2 days. Currently, 11.7% of the shares of the stock are sold short. View XOMA's Current Options Chain. Who are some of XOMA's key competitors? Some companies that are related to XOMA include Rocket Pharmaceuticals (RCKT), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), AC Immune (ACIU), Cara Therapeutics (CARA), Aptinyx (APTX), GlycoMimetics (GLYC), Abeona Therapeutics (ABEO), Vectura Group (VEGPF), Viking Therapeutics (VKTX), Kura Oncology (KURA) and Urogen Pharma (URGN). Who are XOMA's key executives? XOMA's management team includes the folowing people: Mr. James R. Neal, CEO & Director (Age 62)Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)Dr. Deepshikha Datta, Chief Bus. OfficerDr. Kirk W. Johnson Ph.D., VP of Devel. (Age 58) Has XOMA been receiving favorable news coverage? Headlines about XOMA stock have trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XOMA earned a news sentiment score of 0.12 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.18 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. How do I buy shares of XOMA? Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is XOMA's stock price today? One share of XOMA stock can currently be purchased for approximately $24.10. How big of a company is XOMA? XOMA has a market capitalization of $192.89 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe. How can I contact XOMA? XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7239 or via email at [email protected] MarketBeat Community Rating for XOMA (NASDAQ XOMA)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 268 (Vote Underperform)Total Votes: 576MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?